CAS 849217-64-7
:Foretinib
Description:
Foretinib is a small molecule inhibitor primarily targeting receptor tyrosine kinases, particularly MET and VEGFR2, which are involved in various cellular processes such as proliferation, survival, and angiogenesis. It is classified as an experimental anticancer agent and has been investigated for its potential in treating various malignancies, including renal cell carcinoma and other solid tumors. Foretinib exhibits a unique chemical structure that allows it to interfere with the signaling pathways associated with tumor growth and metastasis. The compound is typically administered orally and has been evaluated in clinical trials for its efficacy and safety profile. Its mechanism of action involves blocking the phosphorylation of specific tyrosine residues, thereby inhibiting downstream signaling cascades that promote cancer cell survival and proliferation. As with many targeted therapies, the effectiveness of Foretinib may vary based on the genetic and molecular characteristics of the tumor, highlighting the importance of personalized medicine in oncology.
Formula:C34H34F2N4O6
InChI:InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42)
InChI key:InChIKey=CXQHYVUVSFXTMY-UHFFFAOYSA-N
SMILES:C(NC1=CC(F)=C(OC=2C3=C(C=C(OCCCN4CCOCC4)C(OC)=C3)N=CC2)C=C1)(=O)C5(C(NC6=CC=C(F)C=C6)=O)CC5
Synonyms:- 1,1-Cyclopropanedicarboxamide, N-[3-fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N′-(4-fluorophenyl)-
- 1-N′-[3-Fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
- Exel 2880
- Foretinib
- Gsk 1363089
- Gsk 1363089G
- N-[3-Fluoro-4-[[6-(methyloxy)-7-[[3-(morpholin-4-yl)propyl]oxy]quinolin-4-yl]oxy]phenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
- N-[3-Fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N′-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide
- Xl 880
Filter by
Purity percentage
0
100
|
0
|
50
|
90
|
95
|
100
Found 9 products.
- Lower prices
- Higher prices
- Lower purities
- Higher purities
- Faster estimated delivery
N-[3-Fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide
CAS:Formula:C34H34F2N4O6Purity:98%Color and Shape:SolidMolecular weight:632.6538N-(3-Fluoro-4-((6-Methoxy-7-(3-Morpholinopropoxy)Quinolin-4-Yl)Oxy)Phenyl)-N-(4-Fluorophenyl)Cyclopropane-1,1-Dicarboxamide
CAS:N-(3-Fluoro-4-((6-Methoxy-7-(3-Morpholinopropoxy)Quinolin-4-Yl)Oxy)Phenyl)-N-(4-Fluorophenyl)Cyclopropane-1,1-DicarboxamideFormula:C34H34F2N4O6Purity:98%Molecular weight:632.65Foretinib
CAS:Controlled ProductApplications Foretinib (GSK1363089) is an ATP-competitive inhibitor of hepatocyte growth factor (HGF) and Vascular endothelial growth factor (VEGF) Receptor Tyrosine Kinases.
References Qian, F., et al.: Cancer Res., 69, 8009 (2009); Eder, J., et al.: Clin. Cancer Res., 16, 3507 (2010)Formula:C34H34F2N4O6Color and Shape:NeatMolecular weight:632.65Foretinib
CAS:N-(3-Fluoro-4-((6-methoxy-7-(3-morpholinopropoxy)quinolin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamideFormula:C34H34F2N4O6Purity:98%Molecular weight:632.65Foretinib
CAS:Foretinib (GSK1363089) is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.Formula:C34H34F2N4O6Purity:98.07% - 99.68%Color and Shape:SolidMolecular weight:632.65Ref: TM-T3113
2mg37.00€5mg54.00€10mg74.00€1mL*10mM (DMSO)74.00€25mg126.00€50mg195.00€100mg335.00€500mg803.00€
![N-[3-Fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N'-(4-fluorophenyl…](https://static.cymitquimica.com/products/IN/thumb/DA0038E4.jpg)
